Almost 2 years ago, on May 5, 2020, we published an article reporting that not a single test being used to allegedly detect the COVID-19 virus was approved by the FDA, and that the ones that were granted emergency use authorizations (EUAs) were admitted to be unreliable by the FDA and the pharmaceutical manufacturers.

I included testimony from a reader of Health Impact News who had 43 years of experience in Clinical Diagnostics and was appalled that our nation was being locked down over an alleged virus for which there was no accurate test. See:

Not a Single COVID-19 Test is FDA Approved – Do We Really Know Who has COVID-19 and Who Does Not?

Fast forward now 2 years to today, and the only thing that has changed over these faulty tests is that now there are a lot more of them that have been given EUAs, and still none of them have been granted FDA approval.

This was published on the FDA Roundup News Release on April 1, 2022:

COVID-19 testing updates:

As of today, 425 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 293 molecular tests and sample collection devices, 84 antibody and other immune response tests and 48 antigen tests. There are 74 molecular authorizations and 1 antibody authorization that can be used with home-collected samples. There is one EUA for a molecular prescription at-home test, two EUAs for antigen prescription at-home tests, 15 EUAs for antigen over-the-counter (OTC) at-home tests, and three for molecular OTC at-home tests.

The FDA has authorized 28 antigen tests and nine molecular tests for serial screening programs. The FDA has also authorized 910 revisions to EUA authorizations.